Home » Newsletters » BioWorld Science

BioWorld Science

Jan. 29, 2016

View Archived Issues

DKN-01 plus paclitaxel well tolerated in patients with EC or GEJ

The Hereditary Neuropathy Foundation announces partnership with Acetylon Pharmaceuticals

Chugai reviews key regulatory and pipeline events of fourth quarter 2015

Avax Technologies announces results of its OVAX phase I/II clinical trial

Akashi Therapeutics suspends dosing and enrollment in HT-100 trial

Synthetic lethality approach used to identify antibacterial compounds

FDA grants breakthrough therapy designation for Lynparza as treatment of prostate cancer

Genticel reports phase II trial results for ProCervix

Sophiris reports initial data from phase IIa trial of topsalysin in prostate cancer

Gruenenthal discloses phosphodiesterase 4B inhibitors

Novogen patent reports tropomyosin alpha-3 chain inhibitors

HEC Pharm presents FLT3 inhibitors

Biogen divulges IRAK-4 inhibitors

Cancer Research Technology and MSD form PRMT5 inhibitor collaboration

Phase I study of MERS vaccine begins

Radius Health announces clinical collaboration to evaluate RAD-1901 combination regimens

Giant multivalent glycofullerenes inhibit cell infection by Ebola virus

FDA grants fast track designation to IMC-1 combination for fibromyalgia

FDA approves Merck & Co.'s Zepatier for HCV infection

FDA approves Onzetra Xsail for acute treatment of migraine

Phase III Opdivo trial meets endpoint, stopped early

Cerenis starts phase III trial of CER-001 in familial primary hypoalphalipoproteinemia

ENB Therapeutics' ENB-001 granted FDA orphan designation for melanoma

Agilis and NTU enter collaboration for AADC deficiency gene therapy

FDA approves Halaven in new indication

Biofrontera reports promising phase III results for Ameluz in basal cell carcinoma

FDA says Exelixis's NDA for cabozantinib now complete

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for March 9, 2026.
Cas and effect: Merck’s phase III ripples HIF-2α space
BioWorld
Oddsmakers wasted no time figuring the market chances after Merck & Co. Inc. rolled out data from the phase III Litespark-011 study testing its oral...
Brain’s hidden tau-clearing pathway uncovered
BioWorld Science
Researchers at INSERM and collaborators have identified hypothalamic tanycytes as mediators of tau clearance and shown that their structural and genetic...
News in brief
BioWorld Asia
BioWorld Asia briefs for March 10, 2026
MSD synthesizes α-synuclein PET agents
BioWorld Science
Merck Sharp & Dohme LLC (MSD) has prepared and tested new positron emission tomography (PET) agents for binding and imaging α-synuclein (SNCA) for the diagnosis...